Key result
ATP infusion selectively dilates pulmonary vasculature at lower doses and systemic vessels at higher doses in COPD.
Why the study?
The systemic and pulmonary vascular effects of intravenous adenosine triphosphate infusion in stable COPD patients were not well characterized.
Does intravenous ATP infusion affect pulmonary and systemic hemodynamics in patients with stable COPD?
Does intravenous ATP infusion affect pulmonary and systemic hemodynamics in patients with stable COPD?
Answers are grounded in this paper and cite their sources.
In patients with stable COPD, intravenous ATP infusion acts as a predominant pulmonary vasodilator at low doses, with systemic vasodilation occurring at higher doses.
During stepwise incremental intravenous adenosine triphosphate (ATP) infusion, systemic and pulmonary vascular effects were compared in 10 patients with stable chronic obstructive pulmonary disease (COPD). Pulmonary vasodilation was: 1) predominant and maximal as early as the lowest dose infusion (0.1 mumol.kg-1.min-1) with pulmonary arterial mean pressure (Ppa) (-16%; p less than 0.01) and pulmonary vascular resistance (PVR) decreases (-28%; p less than 0.005) and simultaneous increasing delta PVR/delta SVR ratio; 2) associated with worsening hypoxaemia (-14%; p less than 0.001), but also with increasing alveolar-arterial oxygen pressure difference (P(A-a)O2) and venous admixture (Qs/Qt) suggesting some inhibition of hypoxic pulmonary vasoconstriction. Systemic vasodilation was: 1) clearly dose-dependent, but only reached significant level at 0.2 mumol.kg-1.min-1 with systemic arterial mean pressure (Psa) (-12.5%; p less than 0.05) and systemic vascular resistance (SVR) decreases (-30%; p less than 0.01); 2) associated with arterial carbon dioxide tension (PaCO2) decrease (-12.5%; p less than 0.005) and recurring uncontrollable hyperpnoea, suggesting a ventilatory stimulatory effect of ATP in man. In patients with stable COPD, ATP infusion has dual acute haemodynamic effects depending on the dose-level. The predominant pulmonary vasodilating effect occurs as early as the lowest dose-levels without any further increase of pulmonary vasodilation. This contrasts with the dose-related systemic vasodilation effect. Such a dual haemodynamic effect is an indirect indication of in vivo lung metabolism of ATP.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (1990) studied stable chronic obstructive pulmonary disease (COPD) (n=10). Adenosine triphosphate (ATP) was evaluated on Systemic and pulmonary vascular effects. In patients with stable COPD, ATP infusion has dual acute haemodynamic effects, with predominant pulmonary vasodilation at lower doses and dose-related systemic vasodilation at higher doses.
Synapse has enriched 10 related papers. Consider them for comparative context: